NCT03981094 is a Phase 1 clinical trial of BMS-986278 in Idiopathic Pulmonary Fibrosis (IPF), sponsored by Bristol-Myers Squibb.

Who is sponsoring NCT03981094?

NCT03981094 is sponsored by Bristol-Myers Squibb.

What drugs are being tested in NCT03981094?

Interventions in NCT03981094: BMS-986278, Pirfenidone.

What condition does NCT03981094 study?

NCT03981094 studies Idiopathic Pulmonary Fibrosis (IPF).

Is NCT03981094 still recruiting?

NCT03981094 is currently completed. Last updated 15 May 2020.

Last reviewed 2020-05-15 · How we verify

NCT03981094

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants

Completed Phase 1 Last updated 15 May 2020

What this trial tests

Phase 1 trial testing BMS-986278 in Idiopathic Pulmonary Fibrosis (IPF) in 22 participants. Completed in 30 July 2019.

Timeline

10 May 2019

Primary endpoint
27 July 2019

30 July 2019

Quick facts

Lead sponsor	Bristol-Myers Squibb
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	22
Start date	10 May 2019
Primary completion	27 July 2019
Estimated completion	30 July 2019
Sites	1 location across United States

Drugs / interventions tested

BMS-986278 — full drug profile →
Pirfenidone — full drug profile →

Conditions studied

Idiopathic Pulmonary Fibrosis (IPF) — all drugs for Idiopathic Pulmonary Fibrosis (IPF) →

Sponsor

Bristol-Myers Squibb — full company profile →

Who can join

Adults 21 to 65, any sex, with Idiopathic Pulmonary Fibrosis (IPF). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objectives of this study are to characterize the PK of BMS-986278 after administration of a single dose of BMS-986278 alone or in combination with pirfenidone, as well as to characterize the PK of pirfenidone after administration of a single dose of pirfenidone alone or in combination with BMS-986278

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Inhibitors of the Autotaxin-Lysophosphatidic Acid Axis and Their Potential in the Treatment of Interstitial Lung Disease: Current Perspectives.
Zulfikar S, Mulholland S, Adamali H, Barratt SL. · · 2020 · cited 28× · PMID 32765123 · DOI 10.2147/cpaa.s228362
Advances in Selenium and Related Compounds Inhibiting Multi-Organ Fibrosis.
Xiao X, Huang G, Yu X, Tan Y. · · 2025 · cited 3× · PMID 39830783 · DOI 10.2147/dddt.s488226

Verify or expand the search:

Other trials of BMS-986278

Trials testing the same drug.

NCT07441408 — Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis · Phase 3 · not yet recruiting
NCT07422298 — A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants · Phase 1 · recruiting
NCT06746402 — A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Car · Phase 1 · completed
NCT06723535 — A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal D · Phase 1 · completed
NCT06425198 — Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of · Phase 1 · completed

Other recruiting trials for Idiopathic Pulmonary Fibrosis (IPF)

Currently open trials in the same condition.

NCT07482917 — Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 Trial · NA · recruiting
NCT07486206 — Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial · NA · recruiting
NCT06968845 — A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis · Phase 2 · recruiting
NCT07466420 — Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases. · NA · recruiting
NCT07464912 — A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic · Phase 3 · recruiting

Other Bristol-Myers Squibb trials

Trials by the same sponsor.

NCT07441408 — Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis · Phase 3 · not yet recruiting
NCT07459543 — A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unre · Phase 4 · not yet recruiting
NCT07285798 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder · Phase 3 · not yet recruiting
NCT07284745 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism · Phase 3 · not yet recruiting
NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03981094 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bristol-Myers Squibb
Last refreshed: 15 May 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03981094.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing